[1] M. Prince, R. Bryce, E. Albanese, A. Wimo, W. Ribeiro, C.P. Ferri, The global pre- valence of dementia: a systematic review and metaanalysis, Alzheimers Dement. 9 (1) (2013) 63–75 (e62).
[2] M.G. Erkkinen, M.O. Kim, M.D. Geschwind, Clinical neurology and epidemiology of the major neurodegenerative diseases, Cold Spring Harb. Perspect. Biol. 10 (4) (2018).
[3] R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, E. Kokmen, Mild cognitive impairment: clinical characterization and outcome, Arch. Neurol. 56 (3) (1999) 303–308.
[4] R.C. Petersen, R. Doody, A. Kurz, R.C. Mohs, J.C. Morris, P.V. Rabins, K. Ritchie, M. Rossor, L. Thal, B. Winblad, Current concepts in mild cognitive impairment, Arch. Neurol. 58 (12) (2001) 1985–1992.
[5] S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C. Jack, W. Jagust, J.Q. Trojanowski, A.W. Toga, L. Beckett, The Alzheimer’s disease neuroimaging initiative, Neuroimaging Clin. N. Am. 15 (4) (2005) 869–877 (xi-xii).
[6] M.T. Heneka, M.J. Carson, J. El Khoury, G.E. Landreth, F. Brosseron, D.L. Feinstein, A.H. Jacobs, T. Wyss-Coray, J. Vitorica, R.M. Ransohoff, K. Herrup, S.A. Frautschy, B. Finsen, G.C. Brown, A. Verkhratsky, K. Yamanaka, J. Koistinaho, E. Latz, A. Halle, G.C. Petzold, T. Town, D. Morgan, M.L. Shinohara, V.H. Perry, C. Holmes, N.G. Bazan, D.J. Brooks, S. Hunot, B. Joseph, N. Deigendesch, O. Garaschuk, E. Boddeke, C.A. Dinarello, J.C. Breitner, G.M. Cole, D.T. Golenbock, M.P. Kummer, Neuroinflammation in Alzheimer’s disease, Lancet Neurol. 14 (4) (2015) 388–405.
[7] A. Surendranathan, J.B. Rowe, J.T. O’Brien, Neuroinflammation in Lewy body de- mentia, Parkinsonism Relat. Disord. 21 (12) (2015) 1398–1406.
[8] M.A. Meraz-Rios, D. Toral-Rios, D. Franco-Bocanegra, J. Villeda-Hernandez, V. Campos-Pena, Inflammatory process in Alzheimer’s disease, Front. Integr. Neurosci. 7 (2013) 59.
[9] M.M. Wang, D. Miao, X.P. Cao, L. Tan, L. Tan, Innate immune activation in Alzheimer’s disease, Ann. Transl. Med. 6 (10) (2018) 177.
[10] F. Brosseron, M. Krauthausen, M. Kummer, M.T. Heneka, Body fluid cytokine levels in mild cognitive impairment and Alzheimer’s disease: a comparative overview, Mol. Neurobiol. 50 (2) (2014) 534–544.
[11] C. Domingues, E.S.O.A.B. da Cruz, A.G. Henriques, Impact of cytokines and che- mokines on Alzheimer’s disease Neuropathological hallmarks, Curr. Alzheimer Res. 14 (8) (2017) 870–882.
[12] B.S. Diniz, A.L. Teixeira, E.B. Ojopi, L.L. Talib, V.A. Mendonca, W.F. Gattaz, O.V. Forlenza, Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer’s disease, J. Alzheimers Dis. 22 (4) (2010) 1305–1311.
[13] J. Kalman, A. Juhasz, G. Laird, P. Dickens, T. Jardanhazy, A. Rimanoczy, I. Boncz, W.L. Parry-Jones, Z. Janka, Serum interleukin-6 levels correlate with the severity of dementia in down syndrome and in Alzheimer’s disease, Acta Neurol. Scand. 96 (4) (1997) 236–240.
[14] D. Galimberti, C. Fenoglio, C. Lovati, E. Venturelli, I. Guidi, B. Corra, D. Scalabrini, F. Clerici, C. Mariani, N. Bresolin, E. Scarpini, Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease, Neurobiol. Aging 27 (12) (2006) 1763–1768.
[15] C. Laske, K. Stellos, N. Hoffmann, E. Stransky, G. Straten, G.W. Eschweiler, T. Leyhe, Higher BDNF serum levels predict slower cognitive decline in Alzheimer’s disease patients, Int. J. Neuropsychopharmacol. 14 (3) (2011) 399–404.
[16] M.G. Dik, C. Jonker, C.E. Hack, J.H. Smit, H.C. Comijs, P. Eikelenboom, Serum inflammatory proteins and cognitive decline in older persons, Neurology 64 (8) (2005) 1371–1377.
[17] J.D. Weaver, M.H. Huang, M. Albert, T. Harris, J.W. Rowe, T.E. Seeman, Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging, Neurology 59 (3) (2002) 371–378.
[18] K. Westin, P. Buchhave, H. Nielsen, L. Minthon, S. Janciauskiene, O. Hansson, CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease, PLoS One 7 (1) (2012) e30525.
[19] P.S. Aisen, R.C. Petersen, M.C. Donohue, A. Gamst, R. Raman, R.G. Thomas, S. Walter, J.Q. Trojanowski, L.M. Shaw, L.A. Beckett, C.R. Jack Jr., W. Jagust, A.W. Toga, A.J. Saykin, J.C. Morris, R.C. Green, M.W. Weiner, Clinical Core of the Alzheimer’s disease neuroimaging initiative: progress and plans, Alzheimers Dement. 6 (3) (2010) 239–246.
[20] C. Schwarz, E. Fletcher, C. DeCarli, O. Carmichael, Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR, Inform. Process. Med. Imaging 21 (2009) 239–251.
[21] S.E. O’Bryant, L. Johnson, M. Edwards, H. Soares, M.D. Devous, S. Ross, G. Rohlfing, J. Hall, The link between C-reactive protein and Alzheimer’s disease among Mexican Americans, J. Alzheimers Dis. 34 (3) (2013) 701–706.
[22] E. King, J.T. O’Brien, P. Donaghy, C. Morris, N. Barnett, K. Olsen, C. Martin-Ruiz, J.P. Taylor, A.J. Thomas, Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias, J. Neurol. Neurosurg. Psychiatry 89 (4) (2018) 339–345.
[23] J.T. Sutliffe, L.D. Wilson, H.D. de Heer, R.L. Foster, M.J. Carnot, C-reactive protein response to a vegan lifestyle intervention, Complement. Ther. Med.. 23 (1) (2015) 32–37.
[24] E.J. van Dijk, N.D. Prins, S.E. Vermeer, H.A. Vrooman, A. Hofman, P.J. Koudstaal, M.M. Breteler, C-reactive protein and cerebral small-vessel disease: the Rotterdam scan study, Circulation 112 (6) (2005) 900–905.
[25] C. Gong, D. Wei, Y. Wang, J. Ma, C. Yuan, W. Zhang, G. Yu, Y. Zhao, A meta- analysis of C-reactive protein in patients with Alzheimer’s disease, Am. J. Alzheimers Dis. Other Dement. 31 (3) (2016) 194–200.
[26] A. Ng, W.W. Tam, M.W. Zhang, C.S. Ho, S.F. Husain, R.S. McIntyre, R.C. Ho, IL-1beta, IL-6, TNF- alpha and CRP in elderly patients with depression or Alzheimer’s disease: systematic review and meta-analysis, Sci. Rep. 8 (1) (2018) 12050.
[27] W.W. Cruikshank, H. Kornfeld, D.M. Center, Interleukin-16, J. Leukoc. Biol. 67 (6) (2000) 757–766.
[28] M. Motta, R. Imbesi, M. Di Rosa, F. Stivala, L. Malaguarnera, Altered plasma cy- tokine levels in Alzheimer’s disease: correlation with the disease progression, Immunol. Lett. 114 (1) (2007) 46–51.
[29] P. Angelis, S. Scharf, A. Mander, F. Vajda, N. Christophidis, Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer’s disease, Neurosci. Lett. 244 (2) (1998) 106–108.
[30] H. Hampel, T. Sunderland, H.U. Kotter, C. Schneider, S.J. Teipel, F. Padberg, R. Dukoff, J. Levy, H.J. Moller, Decreased soluble interleukin-6 receptor in cere- brospinal fluid of patients with Alzheimer’s disease, Brain Res. 780 (2) (1998) 356–359.
[31] C.E. Teunissen, D. Lutjohann, K. von Bergmann, F. Verhey, F. Vreeling, A. Wauters, E. Bosmans, H. Bosma, M.P. van Boxtel, M. Maes, J. Delanghe, H.J. Blom, M.M. Verbeek, P. Rieckmann, C. De Bruijn, H.W. Steinbusch, J. de Vente, Combination of serum markers related to several mechanisms in Alzheimer’s dis- ease, Neurobiol. Aging 24 (7) (2003) 893–902.
[32] Y. Hasegawa, M. Sawada, N. Ozaki, T. Inagaki, A. Suzumura, Increased soluble tumor necrosis factor receptor levels in the serum of elderly people, Gerontology. 46 (4) (2000) 185–188.
[33] E. Richartz, E. Stransky, A. Batra, P. Simon, P. Lewczuk, G. Buchkremer, M. Bartels, K. Schott, Decline of immune responsiveness: a pathogenetic factor in Alzheimer’s disease? J. Psychiatr. Res. 39 (5) (2005) 535–543.
[34] R.H. Myers, E.J. Schaefer, P.W. Wilson, R. D’Agostino, J.M. Ordovas, A. Espino, R. Au, R.F. White, J.E. Knoefel, J.L. Cobb, K.A. McNulty, A. Beiser, P.A. Wolf, Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study, Neurology 46 (3) (1996) 673–677.
[35] D. Tsuang, J.B. Leverenz, O.L. Lopez, R.L. Hamilton, D.A. Bennett, J.A. Schneider, A.S. Buchman, E.B. Larson, P.K. Crane, J.A. Kaye, P. Kramer, R. Woltjer, J.Q. Trojanowski, D. Weintraub, A.S. Chen-Plotkin, D.J. Irwin, J. Rick, G.D. Schellenberg, G.S. Watson, W. Kukull, P.T. Nelson, G.A. Jicha, J.H. Neltner, D. Galasko, E. Masliah, J.F. Quinn, K.A. Chung, D. Yearout, I.F. Mata, J.Y. Wan, K.L. Edwards, T.J. Montine, C.P. Zabetian, APOE epsilon4 increases risk for de- mentia in pure synucleinopathies, JAMA Neurol. 70 (2) (2013) 223–228.
[36] C.C. Liu, C.C. Liu, T. Kanekiyo, H. Xu, G. Bu, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy, Nat. Rev. Neurol. 9 (2) (2013) 106–118.
[37] J.A. Wood, P.L. Wood, R. Ryan, N.R. Graff-Radford, C. Pilapil, Y. Robitaille, R. Quirion, Cytokine indices in Alzheimer’s temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein, Brain Res. 629 (2) (1993) 245–252.
[38] M. Hull, S. Strauss, M. Berger, B. Volk, J. Bauer, The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer’s disease, Behav. Brain Res. 78 (1) (1996) 37–41.
[39] M. Rothaug, C. Becker-Pauly, S. Rose-John, The role of interleukin-6 signaling in nervous tissue, Biochim. Biophys. Acta 1863 (6 Pt A) (2016) 1218–1227.
[40] A. Spooren, K. Kolmus, G. Laureys, R. Clinckers, J. De Keyser, G. Haegeman, S. Gerlo, Interleukin-6, a mental cytokine, Brain Res. Rev. 67 (1–2) (2011) 157–183.
[41] E. Fattori, D. Lazzaro, P. Musiani, A. Modesti, T. Alonzi, G. Ciliberto, IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage, Eur. J. Neurosci. 7 (12) (1995) 2441–2449.
[42] G.E. Ringheim, A.M. Szczepanik, W. Petko, K.L. Burgher, S.Z. Zhu, C.C. Chao, Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex, Brain Res. Mol. Brain Res. 55 (1) (1998) 35–44.
[43] Z. Qiu, D.L. Gruol, Interleukin-6, beta-amyloid peptide and NMDA interactions in rat cortical neurons, J. Neuroimmunol. 139 (1–2) (2003) 51–57.
[44] P. Chakrabarty, K. Jansen-West, A. Beccard, C. Ceballos-Diaz, Y. Levites, C. Verbeeck, A.C. Zubair, D. Dickson, T.E. Golde, P. Das, Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition, FASEB J. 24 (2) (2010) 548–559.
[45] P. Marz, U. Otten, S. Rose-John, Neural activities of IL-6-type cytokines often de- pend on soluble cytokine receptors, Eur. J. Neurosci. 11 (9) (1999) 2995–3004.
[46] A. Valerio, M. Ferrario, M. Dreano, G. Garotta, P. Spano, M. Pizzi, Soluble inter- leukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro differentiation of purified rat oligodendroglial lineage cells, Mol. Cell. Neurosci. 21 (4) (2002) 602–615.
[47] E.M. Briso, O. Dienz, M. Rincon, Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells, J. Immunol. (Baltimore, Md: 1950) 180 (11) (2008) 7102–7106.
[48] M. Bagli, A. Papassotiropoulos, H. Hampel, K. Becker, F. Jessen, K. Burger, U. Ptok, M.L. Rao, H.J. Moller, W. Maier, R. Heun, Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer’s disease. Results of a pilot study, Eur. Arch. Psychiatry Clin. Neurosci. 253 (1) (2003) 44–48.
[49] P.C. Haddick, J.L. Larson, N. Rathore, T.R. Bhangale, Q.T. Phung, K. Srinivasan, D.V. Hansen, J.R. Lill, M.A. Pericak-Vance, J. Haines, L.A. Farrer, J.S. Kauwe, G.D. Schellenberg, C. Cruchaga, A.M. Goate, T.W. Behrens, R.J. Watts, R.R. Graham, J.S. Kaminker, M. van der Brug, A common variant of IL-6R is as- sociated with elevated IL-6 pathway activity in Alzheimer’s disease brains, J. Alzheimers Dis. 56 (3) (2017) 1037–1054.
[50] C.R. Jack Jr., D.A. Bennett, K. Blennow, M.C. Carrillo, B. Dunn, S.B. Haeberlein, D.M. Holtzman, W. Jagust, F. Jessen, J. Karlawish, E. Liu, J.L. Molinuevo, T. Montine, C. Phelps, K.P. Rankin, C.C. Rowe, P. Scheltens, E. Siemers, H.M. Snyder, R. Sperling, NIA-AA research framework: toward a biological defini- tion of Alzheimer’s disease, Alzheimers Dement. 14 (4) (2018) 535–562.
[51] C.R. Jack Jr., D.M. Holtzman, R. Sperling, Dementia is not synonymous with Alzheimer’s disease, Sci. Transl. Med. 11 (522)(2019).